Clinical Stage Pharma

Developing small molecules for the treatment of gastric acid related diseases.

About Cinclus Pharma
Cinclus Pharma

The Next Leap Forward

Blockbuster Proton Pump Inhibitors (PPIs) such as Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. The time has now come for Potassium-Competitive Acid Blockers (P-CABs) to take the next leap forward in the treatment of acid-related diseases. Cinclus Pharma’s clinical stage drug candidate linaprazan glurate takes a new approach to provide improved management of GERD and for the treatment of Helicobacter Pylori (H.Pylori) infection.

Learn more

Cinclus Pharma man with GERD startpage

Latest pressreleases


cinclus pharma illustration of linazapran molecule grey
Our lead asset

Linaprazan glurate

Built on world-leading industrial tradition, linaprazan glurate is a gastric acid blocker and therapy with great potential for healing GERD. Several clinical Phase I trials have been successfully completed and in 2022 the clinical Phase II trial was completed. Linaprazan glurate represents an improved mode of action with the potential for superior clinical efficacy and beneficial pharmacokinetic profile compared to PPIs.

Learn more

Latest News


Cinclus Redeye Growth Day 03

Presentation of the company and the development of linaprazan glurate from Redeye Transactions

Here you can watch the full presentation (in Swedish) of Cinclus Pharma and the development of linaprazan glurate, held by CEO Christer Ahlberg at Redeye Transactions June 13th.

Cinclus News Christer Finansieringsevent 02

Presentation of the company and the development of linaprazan glurate from Aktiespararnas event June 12th

Here you can watch the full presentation (in Swedish) of Cinclus Pharma and the development of linaprazan glurate, held by CEO Christer Ahlberg at Aktiespararnas event June 12th.

Cinclus News Image Notering

Cinclus Pharma announces listing on Nasdaq Stockholm and offering of ordinary shares as well as publishes related prospectus

Cinclus Pharma Holding AB (publ) (“Cinclus Pharma” or the “Company”), a Swedish clinical stage pharmaceutical company, has resolved to diversify the shareholder base through an offering of newly issued ordinary shares (the “Offering”) and has at the…

cinclus pharma bistro with greenery in the ceiling
Reflux diseases

AFFECTING SOCIAL LIFE AND WELLNESS

Most people can relate to discomfort from heartburn and regurgitation, two of the most common symptoms caused by GERD. Symptoms often occur during or after eating and drinking, which affects both motivation and the ability to enjoy social activities such as picnics, dinners, events, or just a cup of coffee with friends. More severe stages of GERD with the presence of esophageal erosions (eGERD) or ulcerations (complicated GERD) can be very painful.

Learn more about GERD

"Cinclus Pharma wants to accomplish a paradigm shift in the treatment of acid-related diseases. We will do this by registering and launching our effective P-CAB linaprazan glurate and making it available worldwide."

CHRISTER AHLBERG

CEO CINCLUS PHARMA